NVS Novartis AG
Company Analysis
Latest News
🟢 Novartis is trading 4.8% up in after-hours trading
Novartis is trading at $158.43, up 4.84% after hours; the supplied indicators do not establish a cause for the rebound. - On October 23, Novartis reported...
🟢 Novartis is trading 3.02% up today as healthcare gains provide context
Novartis is trading at $151.32, up 3.02%, with healthcare-sector strength the main context for the gain. - On October 15, healthcare reportedly rose 2.12%;...
🟢 Novartis is trading 3.04% up today amid a healthcare-sector rally
Novartis is trading 3.04% up now at $146.74, alongside a healthcare-sector rally. - Healthcare was up 1.64% during regular trading; supplied context attributes...
Novartis Strikes Abogen RNA Deal Worth Up to $7.8B
Novartis AG announced a licensing and option agreement with China’s Abogen Biosciences to develop RNA-encoded therapeutics. The deal includes a $575 million...
Novartis buys Sironax brain tech for $125M, tackling blood-brain barrier
Novartis AG exercised its exclusive option to acquire the global rights to Sironax’s proprietary brain delivery platform on September 17, 2026. The transaction...
🔴 Novartis is trading 12.51% down today after del-desiran failed to show significant improvement
Novartis is trading 12.51% down at $139.97 after del-desiran failed to achieve statistically significant improvement in the Phase III HARBOR trial for myotonic...
Novartis Loses Two Billion-Dollar Bets in One Week — Can Its Growth Story Survive the Wreckage?
Shares of Novartis plunged 12.6% to $139.79 Tuesday after the Swiss drugmaker disclosed that its experimental muscle-wasting drug failed a crucial late-stage...
🔴 Novartis is trading 12.63% down in pre-market after del-desiran missed HARBOR's primary endpoint
Novartis is trading 12.63% down at $139.79 after reporting that del-desiran failed to achieve its primary endpoint in the Phase III HARBOR study for myotonic...
🔴 Novartis is trading 3.12% down in after-hours trading after three deaths prompt eight trial pauses
Novartis is trading 3.12% down at $155 in after-hours trading after pausing eight autoimmune and neurological rap-cel trials following three patient deaths. -...
Novartis strikes $3.22 billion Alteogen deal, simplifying drug delivery
Novartis AG signed a strategic partnership and license agreement with South Korean biotech Alteogen Inc. The collaboration utilizes Hybrozyme technology to...
🟢 Novartis is trading 6.98% up today after remibrutinib met primary Phase III MS endpoints
Novartis is trading 6.98% up at $162.68 after remibrutinib met the primary endpoints in two Phase III relapsing multiple sclerosis trials, reducing relapse...
Novartis Scores a Big MS Drug Win, but Three Patient Deaths in a Separate Program Cloud the Celebration — Can the Stock Hold Its Gains?
Shares of Novartis jumped 4.3% to $158.55 on September 1 after the Swiss drugmaker reported that its oral pill for relapsing multiple sclerosis cleared two...
🟢 Novartis is trading 4.3% up in pre-market after positive Phase III remibrutinib results
Novartis is trading 4.27% up now at $158.55 after announcing positive Phase III REMODEL-1/-2 results for remibrutinib in relapsing multiple sclerosis. -...
Dodge & Cox Slashes Novartis (NVS) Position by 89%
Value investing giant Dodge & Cox drastically reduced its stake in Swiss pharmaceutical company Novartis AG (NVS) by 89% during the second quarter of 2026. The...
🔴 Novartis is trading 4.52% down in after-hours trading
Novartis is trading at $153.08, down 4.52% in after-hours trading, with no clear negative company-specific catalyst identified. • Regular session gained 3.74%...
🟢 Novartis is trading 3.22% up today as healthcare stocks rally broadly
Novartis is trading 3.22% up at $159.52 as healthcare stocks rally broadly, with XLV up 3.23% during regular trading. - Investors are rotating toward...
Novartis AG Q2 2026 Earnings Preview: What Analysts Expect on July 21, 2026
Novartis is scheduled to report Q2 2026 results with a consensus revenue estimate of $14.50 billion and an EPS of $2.20, while the stock currently trades at...
Novartis AG Q1 2026 Earnings Preview: What Analysts Expect on April 28, 2026
Novartis AG enters its Q1 2026 earnings report with a consensus revenue estimate of $13.56 billion (+2.5% YoY) and an EPS expectation of $2.11 (-7.5% YoY),...
Novartis Acquires Pikavation for $2 Billion, Defending Breast Cancer Market Lead
Novartis has agreed to acquire Pikavation Therapeutics, a subsidiary of Synnovation Therapeutics. The deal includes an upfront payment of $2 billion. Potential...